The refusal for approval was based on documented deficiencies in the trial protocol and methodology (derived controls and potency assay) for the aGVHD trial. The FDA bent over backwards to allow MSB to try and present new evidence and they failed on two BLA submissions. MSB has repeatedly challenged the FDA decisions and refused to take carry out the FDA's recommended pathway to approval. The totality of the data doesn't support efficacy at all (repeated failed trials). Sorry, MSB don't have a leg to stand on. See Southoz's criticisms. But if you are relying on Mesoblast to threaten the FDA with litigation as a pathway to approval, then that's even more desperate than SI's cap raise and proposals.
- Forums
- ASX - By Stock
- MSB
- Ann: Change of Director's Interest Notice - Silviu Itescu
Ann: Change of Director's Interest Notice - Silviu Itescu, page-113
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $4.734M | 4.018M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 91395 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 113220 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 81319 | 1.160 |
21 | 92137 | 1.155 |
14 | 105511 | 1.150 |
14 | 206116 | 1.145 |
9 | 199738 | 1.140 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 103580 | 12 |
1.170 | 111075 | 18 |
1.175 | 51315 | 8 |
1.180 | 77792 | 10 |
1.185 | 36343 | 4 |
Last trade - 14.53pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online